Advertisement

Rheumatology International

, Volume 30, Issue 6, pp 849–850 | Cite as

Abatacept as an option therapy in difficult to treat psoriatic arthritis

  • Francisco José Fernandes Vieira
  • Maria Roseli Monteiro CalladoEmail author
  • Walber Pinto Vieira
Letter to the Editor

Abstract

Psoriatic arthritis (PA) is an inflammatory arthritis associated with cutaneous psoriasis. Treatment consists of non-steroidal anti-inflammatory drugs, corticosteroids at low doses and disease-modifying anti-rheumatic drugs. We relate a case of PA that after the fault of the handlings convecionais to sick we opted for an empiric treatment with Abatacept, based on the current knowledge on the physiopathology of PA and its low hepatotoxicity found in an animal model.

Keywords

Psoriatic arthritis Abatacept 

Notes

Conflicts of interest statement

The authors declare that they have no conflict of interest.

References

  1. 1.
    Fitzgerald O (2008) Psoriatic arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS (eds) Kelley’s textbook of rheumatology. Available via DIALOG. http://www.mdconsult.com/das/book/body/132831804-2/0/1807/528.html. Accessed 21 Apr 2009
  2. 2.
    Ritchlin C (2008) Psoriatic arthritis: pathology and pathogenesis. In: Klippel JH, Stone JH, Crofford LJ, White PH (eds) Primer on the rheumatic diseases. Springer Science, New York, pp 178–184CrossRefGoogle Scholar
  3. 3.
    Jones G, Crotty M, Brooks P (2008) Intervenciones para el tratamiento de la artritis psoriásica (Cochrane Review). In: La Biblioteca Cochrane Plus, Issue 3. Available via DIALOG. http://www.update-software.com/abstractsES/AB000212-ES.htm. Accessed 21 Apr 2009
  4. 4.
    Nash P, Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64(Suppl II):ii74–ii77. doi: 10.1136/ard.2004.030783 CrossRefPubMedGoogle Scholar
  5. 5.
    Gartehner G, Hansen RA, Thieda P, Jonas B, Lohr KN, Carey T (2005) Drug class review on target immune modulators. Available via DIALOG. http://www.ohsu.edu/drugeffectiveness. Accessed 1 Dec 2008
  6. 6.
    Baker H, Ryan TJ (1968) Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 80:771–793. doi: 10.1111/j.1365-2133.1968.tb11947.x CrossRefPubMedGoogle Scholar
  7. 7.
    Turkiewicz AM, Moreland LW (2007) Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 56:1051–1066. doi: 10.1002/art.22489 CrossRefPubMedGoogle Scholar
  8. 8.
    Kuek A, Hazleman BL, Ostör AJ (2007) Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 83(978):251–260. doi: 10.1136/pgmj.2006.052688 CrossRefPubMedGoogle Scholar
  9. 9.
    Nakayama Y, Shimizu Y, Hirano K, Ebata K, Minemura M, Watanabe A, Sugiyama T (2005) CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. Hepatology 42(4):915–924. doi: 10.1002/hep.20872 CrossRefPubMedGoogle Scholar
  10. 10.
    Westhovens R, Verschueren P (2008) Translating co-stimulation blockade into clinical practice. Arthritis Res Ther 10(Suppl 1):S4. doi: 10.1186/ar2415 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Francisco José Fernandes Vieira
    • 1
  • Maria Roseli Monteiro Callado
    • 1
    • 2
    Email author
  • Walber Pinto Vieira
    • 1
  1. 1.Department of RheumatologyFortaleza General HospitalFortalezaBrazil
  2. 2.FortalezaBrazil

Personalised recommendations